Dianthus | Hit Screening

  • Because you demand fast, non-stop, highly sensitive hit screening.

    Because you demand fast, non-stop, highly sensitive hit screening.

    Read
  • Get fast, non-stop, highly sensitive hit screening with Dianthus.2:55

    Get fast, non-stop, highly sensitive hit screening with Dianthus.

    Dianthus removes the complexity of binding interaction measurements for drug discovery screening. Find hits for any target type in any buffer or bioliquid, measure the tightest interactions down to pi

    Watch
  • Going small to win big: Fragment-based screening in drug discovery

    Going small to win big: Fragment-based screening in drug discovery

    Read
  • Have a question about Dianthus?

    Contact Specialist
  • Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Read
  • The NanoTemper Story – Chapter 5: The Dianthus

    The NanoTemper Story – Chapter 5: The Dianthus

    Almost as soon as the Monolith launched, the handful of people that made up NanoTemper in those early days huddled around, brainstorming how to translate the technology into a well-based assay....

    Read
  • Tackle the high-hanging fruits in challenging drug discovery pipelines17:10

    Tackle the high-hanging fruits in challenging drug discovery pipelines

    There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t

    Watch
  • Fast molecular interaction screening of epigenetic gene regulator G9a with fragments from a large chemical space

    Fast molecular interaction screening of epigenetic gene regulator G9a with fragments from a large chemical space

    Read
  • Easily characterize the molecular mechanisms of neurodegenerative diseases

    Easily characterize the molecular mechanisms of neurodegenerative diseases

    Read
  • Fast-track your hit screening assay development with the Buffer Exploration Kit

    Fast-track your hit screening assay development with the Buffer Exploration Kit

    Read
  • Tackle small molecule drug discovery screening challenges with Dianthus17:07

    Tackle small molecule drug discovery screening challenges with Dianthus

    A big hurdle in small molecule drug discovery screening is confidently identifying positive hits in a timely manner. Screening fragment libraries is challenging with current methodologies that are eit

    Watch
  • 3 big takeaways from SLAS on the future of automation and screening

    3 big takeaways from SLAS on the future of automation and screening

    5,200 researchers, representing all of life sciences, gathered in San Diego in late January to discuss the latest in automation and screening solutions. Improvements in automation and screening...

    Read
  • Neurodegenerative Diseases: Studying protein aggregation using NanoTemper instruments16:04

    Neurodegenerative Diseases: Studying protein aggregation using NanoTemper instruments

    Neurodegenerative diseases like Alzheimer’s or Parkinson’s Disease affect millions of people worldwide. Although current treatments may help relieve some of the physical or mental symptoms, there is s

    Watch
  • When aptamers are the better choice over mAbs

    When aptamers are the better choice over mAbs

    Monoclonal antibodies (mAbs) have become the molecule of choice when highly specific molecular recognition is needed for a variety of applications including disease diagnosis and therapy....

    Read
  • 6 ingredients for a successful fragment library

    6 ingredients for a successful fragment library

    Fragment-based drug discovery (FBDD) has become a major strategy to derive novel lead candidates in drug discovery. The principle of FBDD is to start with very small molecular fragments which may...

    Read
  • 4 ways to help you overcome the limitations of current methods in neurodegenerative disease research

    4 ways to help you overcome the limitations of current methods in neurodegenerative disease research

    Read
  • PROTACs: the game-changing technology that promises to tackle “undruggable” proteins

    PROTACs: the game-changing technology that promises to tackle “undruggable” proteins

    Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity. Unfortunately, there are still many target proteins — as much as 85% of the human...

    Read
  • 5 things you must do while in Liverpool for ELRIG Drug Discovery

    5 things you must do while in Liverpool for ELRIG Drug Discovery

      Here’s how to make your trip unforgettable.     1. Immerse yourself in Liverpool’s historic heart at the Royal Albert Dock This is the place to be for many iconic Liverpool attractions. Discover...

    Read
  • 5 things you must do in Barcelona while at SLAS Europe (according to a local)

    5 things you must do in Barcelona while at SLAS Europe (according to a local)

      Here’s how to make your trip memorable.     1. Be awe-inspired at La Sagrada Familia There’s nothing like it anywhere in the world. Architecture, nature and spirituality come together to create...

    Read
  • Answering the demands for a new screening tool for drug discovery with Dianthus

    Answering the demands for a new screening tool for drug discovery with Dianthus

    There’s a gap that exists in screening tools for drug discovery — the need for fast, easy to use and flexible devices isn’t being satisfied. Enter Dianthus, introduced to come to the rescue. At...

    Read
  • Great things start small and so does the discovery of drug candidates

    Great things start small and so does the discovery of drug candidates

    The famous painter Vincent Van Gogh once said, “Great things are done by a series of small things brought together.” This is exactly how drugs are developed by means of fragment-based screening —...

    Read
  • loading
    Loading more...